We help you manage the flood of tests and drugs that emerge in this category daily. Accessed through the Hayes Knowledge Center, our comprehensive Precision Medicine solution focuses on thousands of genetic, genomic, and molecular diagnostic tests and precision medicine therapies addressing the questions our clients most frequently ask:
This report evaluates the use of whole exome sequencing (WES) or whole genome sequencing (WGS) to inform clinical action and improve patient outcomes in children aged ≤ 18 years with undefined neurological phenotypes but no definitive diagnosis following standard diagnostic tests.
This report evaluates the clinical utility of cell-free DNA (cfDNA) (formerly NIPS, NIPT) screening for fetal sex chromosome aneuploidy (SCA) in women with singleton or twin pregnancies.
This report evaluates the analytical validity, clinical validity, and clinical utility of the GeneSight Psychotropic (Myriad Neuroscience) test.
This report evaluates the analytical validity, clinical validity, and clinical utility of the Oncotype DX AR-V7 Nucleus Detect test.
This report evaluates the clinical utility of cell-free DNA (cfDNA) (formerly NIPS, NIPT) screening for fetal trisomy 21, 18, and 13 in women with twin pregnancies.
This report evaluates the clinical utility of genetic testing to detect hereditary cancer 1) high risk and 2) moderate risk gene variants in women with new diagnoses of breast cancer (BC), who are not preselected for other risk factors, to improve disease management.
This report evaluates the AlloSure Kidney test for acute and chronic kidney transplant rejection (antibody-mediated and/or T-cell mediated) in patients for either surveillance or for-cause evaluation.
This report evaluates the analytical validity, clinical validity, and clinical utility of the Nodify XL2 test.
This report evaluates the analytical validity, clinical validity, and clinical utility of the Nodify CDT test.